Richard Marquette spent decades tending his bees — tiny workers that kept his Citrus County property buzzing and his bank account afloat. But when the 84-year-old beekeeper stopped by his vacant lot ...

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or ...

Chronic urticaria affects 17% of patients, with higher age, elevated BMI, and early prednisolone use as key determinants of prolonged disease duration. The study utilized data from the Julius General ...

Novartis received approval from the Food and Drug Administration for Rhapsido (remibrutinib), an oral treatment for adults with chronic spontaneous urticaria. Rhapsido is the first Bruton’s tyrosine ...

Credit: Novartis. Rhapsido is supplied as a 25mg tablet. Treatment with oral remibrutinib resulted in statistically significant improvement in itch and hives symptoms compared with placebo. The Food ...

Novartis has scored the FDA’s approval for a second BTK inhibitor that’s for a non-cancer indication, teeing off a potential competition with Sanofi down the line. The FDA has blessed Novartis’ ...

Remibrutinib is the first Bruton tyrosine kinase (BTK) inhibitor approved for chronic spontaneous urticaria, offering a novel treatment pathway by inhibiting BTK activity. Phase 3 trials showed ...

An anxiety rash looks like small, inflamed patches on the skin and can resemble allergic rashes. Treatment includes managing anxiety through therapy and medications and using soothing lotions or ...

Dear Dr. Roach: I am 78 years old. Breast cancer runs in my family, and I am one of the lucky ones who had a lump that was caught early through an annual mammogram. I had a partial mastectomy, which ...